Table 3 Patients with Ph+ CP CML who maintained or attained MMR after dose reduction (by age and comorbidities).

From: Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study

 

By age

By comorbidities

n/N (%)

<65 years

65–74 years

≥75 years

mCCI 2

mCCI 3

mCCI ≥ 4

No dose reductions (500 mg QD), n

19

10

3

23

6

3

  MMR, n (%)

12 (63.2)

5 (50.0)

1 (33.3)

14 (60.9)

3 (50.0)

1 (33.3)

Dose reduction to 400 mg QD, n

23

9

3

24

6

5

  MMR, n (%)

14 (60.9)

6 (66.7)

2 (66.7)

14 (58.3)

4 (66.7)

4 (80.0)

Dose reduction to 300 mg QD, n

28

7

11

23

8

15

  MMR, n (%)

18 (64.3)

4 (57.1)

9 (81.8)

19 (82.6)

4 (50.0)

8 (53.3)

Dose reduction to 200 mg QD, n

22

5

11

27

6

5

  MMR, n (%)

19 (86.4)

4 (80.0)

9 (81.8)

23 (85.2)

5 (83.3)

4 (80.0)

  1. CML chronic myeloid leukemia, CP chronic phase, mCCI Charlson Comorbidity Index without age component, MMR major molecular response, Ph Philadelphia chromosome, QD once daily.
Back to article page